Literature DB >> 25415151

Impact of low preprocedural transvalvular gradient on cardiovascular mortality following TAVI: an analysis from the FRANCE 2 registry.

Nicolas Amabile1, Helene Agostini, Martine Gilard, Helene Eltchaninoff, Bernard Iung, Patrick Donzeau-Gouge, Karine Chevreul, Jean Fajadet, Pascal Leprince, Alain Leguerrier, Michel Lievre, Alain Prat, Emmanuel Teiger, Marc Laskar, Christophe Caussin.   

Abstract

AIMS: To assess the relationship between a low preprocedural (<40 mmHg) mean transaortic gradient (MTG) and cardiovascular mortality following transcatheter aortic valve implantation (TAVI). METHODS AND
RESULTS: We studied highly symptomatic patients at high surgical risk who underwent TAVI, included in the FRANCE 2 multicentre registry. The primary endpoint was the incidence of any cardiovascular death in the year following the procedure. N=3,933 patients (age=82.8±7.2 years; EuroSCORE=21.8±14.1; left ventricular ejection fraction [LVEF]=55.5±12.6%) were enrolled. Low MTG was present in 23.5% of the cases. The one-year cardiovascular mortality was 13.3%. Cardiovascular survival was significantly lower in low MTG patients compared to the others. Multivariable Cox regression analysis revealed that a low MTG independently predicted cardiovascular death (HR=1.53 [1.15-2.04], p=0.004). Other independent predictors of cardiovascular mortality included preprocedural angina (HR=3.12 [1.64-5.96], p=0.0006); NYHA functional Class III-IV (HR=1.57 [1.07-2.29], p=0.02); severe renal failure (HR=1.50 [1.01-2.24], p=0.04); EuroSCORE (HR=1.01 [1.00-1.02], p=0.01); transapical access (HR=1.59 [1.14-2.22], p=0.006); impaired LVEF (HR=1.66 [1.23-2.27], p=0.0007) and post-procedural moderate to severe periprosthetic regurgitation (HR=2.13 [1.56-2.92], p<0.0001).
CONCLUSIONS: Presence of a low MTG prior to TAVI was associated with a greater risk of cardiovascular death up to one year following the procedure and could be used to identify patients at high risk for adverse cardiovascular outcomes following TAVI.

Entities:  

Mesh:

Year:  2014        PMID: 25415151     DOI: 10.4244/EIJV10I7A144

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  3 in total

1.  Outcome of patients with heart failure after transcatheter aortic valve implantation.

Authors:  Ulrich Fischer-Rasokat; Matthias Renker; Christoph Liebetrau; Maren Weferling; Andreas Rolf; Mirko Doss; Helge Möllmann; Thomas Walther; Christian W Hamm; Won-Keun Kim
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

2.  Risk prediction in patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction undergoing TAVI.

Authors:  Sebastian Ludwig; Alina Goßling; Moritz Seiffert; Dirk Westermann; Jan-Malte Sinning; Atsushi Sugiura; Matti Adam; Victor Mauri; Derk Frank; Hatim Seoudy; Tanja Rudolph; Max Potratz; Lenard Conradi; Niklas Schofer
Journal:  Open Heart       Date:  2022-01

3.  Evolution of transcatheter aortic valve implantation over 7 years: results of a prospective single-centre registry of 2000 patients in a large municipal hospital (TAVIK Registry).

Authors:  Gerhard Schymik; Valentin Herzberger; Jens Bergmann; Peter Bramlage; Lars O Conzelmann; Alexander Würth; Armin Luik; Holger Schröfel; Panagiotis Tzamalis
Journal:  BMJ Open       Date:  2018-10-25       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.